These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 9100247)

  • 1. Is iron involved in pathogenesis of Parkinson's disease--Mössbauer spectroscopy study of substantia nigra in control and disease brains.
    Friedman A; Bauminger ER; Gałazka-Friedman J; Barcikowska M; Hechel D; Nowik I; Marczewska M
    Neurol Neurochir Pol; 1996; 30 Suppl 2():95-103. PubMed ID: 9100247
    [No Abstract]   [Full Text] [Related]  

  • 2. [Mossbauer spectroscopy of iron in substantia nigra in Parkinson disease and controls].
    Friedman A; Bauminger ER; Gałazka-Friedman J; Barcikowska M; Suwalski J; Hechel D; Dymecki J; Nowik I
    Neurol Neurochir Pol; 1994; 28(1 Suppl 1):145-55. PubMed ID: 8065540
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Iron in parkinsonian and control substantia nigra--a Mössbauer spectroscopy study.
    Gałazka-Friedman J; Bauminger ER; Friedman A; Barcikowska M; Hechel D; Nowik I
    Mov Disord; 1996 Jan; 11(1):8-16. PubMed ID: 8771061
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Complex I, iron, and ferritin in Parkinson's disease substantia nigra.
    Mann VM; Cooper JM; Daniel SE; Srai K; Jenner P; Marsden CD; Schapira AH
    Ann Neurol; 1994 Dec; 36(6):876-81. PubMed ID: 7998774
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Morphometric assessment of lesions in the dopaminergic nigrostriatal system in Parkinson disease].
    Bertrand E; Lechowicz W; Szpak GM; Dymecki J
    Neurol Neurochir Pol; 1996; 30(5):751-62. PubMed ID: 9148173
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Iron and ferritin in substantia nigra in Parkinson's disease.
    Jellinger KA; Kienzl E; Rumpelmaier G; Paulus W; Riederer P; Stachelberger H; Youdim MB; Ben-Shachar D
    Adv Neurol; 1993; 60():267-72. PubMed ID: 8420142
    [No Abstract]   [Full Text] [Related]  

  • 7. Iron histochemistry of the substantia nigra in Parkinson's disease.
    Morris CM; Edwardson JA
    Neurodegeneration; 1994 Dec; 3(4):277-82. PubMed ID: 7842298
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mössbauer spectroscopy and ELISA studies reveal differences between Parkinson's disease and control substantia nigra.
    Galazka-Friedman J; Bauminger ER; Koziorowski D; Friedman A
    Biochim Biophys Acta; 2004 Mar; 1688(2):130-6. PubMed ID: 14990343
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Iron in the Parkinsonian substantia nigra.
    Gerlach M; Double K; Riederer P; Hirsch E; Jellinger K; Jenner P; Trautwein A; Youdim MB
    Mov Disord; 1997 Mar; 12(2):258-60. PubMed ID: 9087993
    [No Abstract]   [Full Text] [Related]  

  • 10. Iron-binding characteristics of neuromelanin of the human substantia nigra.
    Double KL; Gerlach M; Schünemann V; Trautwein AX; Zecca L; Gallorini M; Youdim MB; Riederer P; Ben-Shachar D
    Biochem Pharmacol; 2003 Aug; 66(3):489-94. PubMed ID: 12907248
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The history of the research of iron in parkinsonian substantia nigra.
    Friedman A; Galazka-Friedman J
    J Neural Transm (Vienna); 2012 Dec; 119(12):1507-10. PubMed ID: 22941506
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lateral Asymmetry and Spatial Difference of Iron Deposition in the Substantia Nigra of Patients with Parkinson Disease Measured with Quantitative Susceptibility Mapping.
    Azuma M; Hirai T; Yamada K; Yamashita S; Ando Y; Tateishi M; Iryo Y; Yoneda T; Kitajima M; Wang Y; Yamashita Y
    AJNR Am J Neuroradiol; 2016 May; 37(5):782-8. PubMed ID: 26822728
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Specific visualization of neuromelanin-iron complex and ferric iron in the human post-mortem substantia nigra using MR relaxometry at 7T.
    Lee H; Baek SY; Chun SY; Lee JH; Cho H
    Neuroimage; 2018 May; 172():874-885. PubMed ID: 29162523
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pathogenesis of Parkinson's disease.
    Riederer P; Lange KW
    Curr Opin Neurol Neurosurg; 1992 Jun; 5(3):295-300. PubMed ID: 1623255
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Will the mystery of Parkinson's disease be resolved?].
    Lyytinen J; Kaakkola S
    Duodecim; 2005; 121(3):275-84. PubMed ID: 15787285
    [No Abstract]   [Full Text] [Related]  

  • 16. T1-weighted MRI shows stage-dependent substantia nigra signal loss in Parkinson's disease.
    Schwarz ST; Rittman T; Gontu V; Morgan PS; Bajaj N; Auer DP
    Mov Disord; 2011 Aug; 26(9):1633-8. PubMed ID: 21491489
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nigral iron elevation is an invariable feature of Parkinson's disease and is a sufficient cause of neurodegeneration.
    Ayton S; Lei P
    Biomed Res Int; 2014; 2014():581256. PubMed ID: 24527451
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Magnetic resonance imaging markers of Parkinson's disease nigrostriatal signature.
    Péran P; Cherubini A; Assogna F; Piras F; Quattrocchi C; Peppe A; Celsis P; Rascol O; Démonet JF; Stefani A; Pierantozzi M; Pontieri FE; Caltagirone C; Spalletta G; Sabatini U
    Brain; 2010 Nov; 133(11):3423-33. PubMed ID: 20736190
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Controversies about iron in parkinsonian and control substantia nigra.
    Gałazka-Friedman J; Friedman A
    Acta Neurobiol Exp (Wars); 1997; 57(3):217-25. PubMed ID: 9407708
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pathogenesis and animal studies of Parkinson's disease.
    Oertel WH; Kupsch A
    Curr Opin Neurol Neurosurg; 1993 Jun; 6(3):323-32. PubMed ID: 8507901
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.